摘要
目的:探讨乙型肝炎病毒感染与恶性淋巴瘤发病的关系。方法:采用ELISA法检测156例淋巴瘤患者的乙肝5项和肝功能,随机抽取同期住院的156例其他恶性肿瘤患者(排除原发肝脏的恶性肿瘤)和156名健康体检者为对照进行比较。结果:淋巴瘤患者的HBsAg阳性率为22.4%,明显高于其他恶性肿瘤患者(9.6%)和健康对照者(8.3%),差异有统计学意义,P<0.05。以其他恶性肿瘤作参照组,HBsAg阳性患者患淋巴瘤的优势比为2.719,可信区间为1.417～5.218,HBsAg阳性的淋巴瘤患者化疗诱发的肝功能异常率(57.1%)明显高于HBsAg阴性的淋巴瘤患者(27.3%),差异有统计学意义,P<0.05。结论:淋巴瘤患者的HBsAg阳性率明显高于其他恶性肿瘤和普通对照人群,化疗更易引起HBsAg阳性的淋巴瘤患者的肝功异常。
OBJECTIVE：To investigate the relationship between hepatitis B virus （HBV） infection and Malignant lymphoma（ML）.METHODS：The serum markers of HBV and liver function were compared with ELISA technique in 156 ML patients,and 156 other cancer patients （except primary hepatocellular cacinoma）.RESULTS：The positive rate of hepatitis B virus surface antigen（HBsAg）was significantly higher in ML patients（22.4%） than that in other cancer patients（9.6%） and general population（8.3%,P0.05）.Regarding other cancer patients as a reference group,odds ratio（OR） of ML in HBsAg positive population was 2.719,and the 95% confidence interval（95%CI） was 1.417-5.218.The percentage of patients with abnormal liver function increase significantly in HBsAg positive patients more than that of HBsAg negative patients（57.1% vs 27.3%,P0.05）.CONCLUSIONS：The positive rate of HBsAg is higher in ML patients and general population.The cases of ML with HBV are more likely to have liver function damage in chemotherapy.
出处
《中华肿瘤防治杂志》
CAS
2010年第7期485-487,共3页
Chinese Journal of Cancer Prevention and Treatment
